Neurelis, founded with a mission to address unmet medical needs, is a specialty pharmaceutical company that focuses on developing innovative therapies for neurological conditions. The company's core vision is to enhance the quality of life for patients through unique and effective medical solutions. Neurelis offers products and services aimed at treating epilepsy and other central nervous system disorders, leveraging advanced technologies to create differentiated therapeutic options.

Notable individuals affiliated with Neurelis include Phil Haydon, PhD, who is also the President of Sail For Epilepsy, highlighting the company's commitment to community involvement. Neurelis has achieved significant milestones in its field, including the development of cutting-edge treatments that have positively impacted patients' lives. The company's focus on addressing critical gaps in neurological care has positioned it as a key player in the specialty pharmaceutical market, driving meaningful advancements in patient health and well-being.